Over 40 years of literature shows that glycosylation is greatly affected by diseases such as cancer. This opinion article argues the intrinsic advantages of using glycans as disease markers over other biomolecules and the potential of glycan profiling for diagnosing and determining the progression of disease.
No takes yet. Share an insight, caveat, or question.
Lebrilla et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: